Cerevel therapeutics stock price. The stock price is up 1% during the pre Scott M. Get the latest Cerevel Therapeutics Holdings, Inc CERE detailed stock quotes, stock data, Real-Time ECN, charts, stats MT. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of Stock Price Forecast The 9 analysts offering 12-month price forecasts for Cerevel Therapeutics Holdings Inc have a median target of 45. Triano@pfizer. Closing on October 16, 2023. Feb 3, 2024 · Cerevel Therapeutics Holdings Inc (NASDAQ:CERE) shares, rose in value, with the stock price up by 0. 00 expecting CERE to rise to . (673. 8 million and $9. 57 with 2,125,419 million shares trading. The all-time high Cerevel Therapeutics Holdings stock closing price was 44. In depth view into CERE (Cerevel Therapeutics Holdings) stock including the latest price, news, dividend history, earnings information and financials. 93 on Dec 6. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. 6, 2023 – AbbVie Inc. Jul 30, 2021 · Each such public warrant may be exercised by the holder thereof to purchase one share of the Company’s common stock at the exercise price of $11. On average, they anticipate the company's stock price to reach $39. Bain Capital, LP and Pfizer Inc. Their CERE share price targets range from $22. 66 from the previous closing price of $26. 4 days ago · The low in the last 52 weeks of Cerevel Therapeutics Holdings stock was 19. , MBA has two decades of financial management, investor relations, and business planning experience with leading pharmaceutical and biotechnology companies. 00 to a day high of $43. The average Cerevel Therapeutics Holdings stock price prediction forecasts a potential upside of 7. Nov 8, 2023 · Cerevel Therapeutics to Present at Upcoming Investor Conferences. CAMBRIDGE, Mass. Mr. is a clinical-stage biopharmaceutical company. 7 points compared with placebo (p=0. 0 million if the underwriters exercise in full their option to purchase additional shares). Share. Darigabat: A Potential New Treatment For Epilepsy and Panic Disorder. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40. 8 million of shares of its common stock. , a privately-held biopharmaceutical company, where he served as general counsel and corporate secretary of overseeing legal and certain administrative functions including business Dec 6, 2023 · AbbVie will acquire all outstanding Cerevel common stock for $45. (CERE) stock news and headlines to help you in your trading and investing decisions. BOSTON & NEW YORK – October 23, 2018 – Bain Capital, LP and Pfizer Inc. Actively observing the price movement in the last trading, the stock closed the session at $41. 64 with a high price target of $45. (NYSE: PFE) today announced the creation of Cerevel Therapeutics, LLC (“Cerevel”), a new biopharmaceutical company focused on developing drug candidates to treat disorders of the Feb 16, 2024 · What is Cerevel Therapeutics Hldg stock price doing today? As of February 16, 2024, CERE stock price declined to $42. 00 on volume of 730,796 shares. 55% away from the 52-week low. (NYSE: PFE) today announced the creation of Cerevel Therapeutics, LLC (“Cerevel”), a new biopharmaceutical company focused on developing drug candidates to treat disorders of the Ken DiPietro, has served as our Chief Human Resources Officer since April 2019. Jul 30, 2020 · In the news Cerevel Therapeutics and Arya Sciences Acquisition Corp II Announce Business Combination, Creating a Publicly Listed Leader in Neuroscience Drug Development Leading institutional investors commit $320 million through a common stock private investment in public equity (“PIPE”) led by Bain Capital, Perceptive Advisors, Pfizer Inc. We are developing darigabat for the treatment of both epilepsy and panic disorder. Most recently, she served as the chief financial officer of ImmunoGen Nov 1, 2023 · Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon investor webcast scheduled for December 11, 2023 Conference call today at 8:00 a. (212) 733-3901. 87, which is 3. 03% as of 10:48 AM on Monday, Dec 4. According to the current price, Cerevel Therapeutics Holdings is 209. The Cerevel Therapeutics Holdings 52-week high stock price is 42. (CERE) stock. Download PDF. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases Aug 2, 2023 · Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock. Darigabat was rationally designed as an orally-bioavailable, twice-daily positive allosteric modulator (PAM) that selectively targets GABA A receptors containing alpha-2/3/5 subunits. Dec 4, 2023 · What's Happening With CERE Stock Today? Cerevel Therapeutics Holdings Inc (CERE) stock has gained 6. Jun 29, 2021 · Here's Why Cerevel Therapeutics Stock Is Shooting Through the Roof Today. $40. Current Cerevel prices are $41, leaving almost a 10% Darigabat. 2 million of stock-based compensation expense, compared to $0. 00 to $45. Cerevel Therapeutics Holdings Insider Sold Shares Worth $571,972, According to a Recent SEC Filing. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. 7 billion deal to acquire the neurological drug developer. 51%. 3 days ago · 11 Wall Street analysts have issued 12 month target prices for Cerevel Therapeutics' shares. Suneet Varma is global and U. Company Prepared to Move Lead Asset to Phase 3 in Parkinson’s Disease in 2019. Discover historical prices for CERE stock on Yahoo Finance. 59. 88. D. The average twelve-month price prediction for Cerevel Therapeutics is $39. Complete Cerevel Therapeutics Holdings Inc. View real-time stock prices and stock quotes for a full financial overview. Susan Altschuller, Ph. View real-time CERE stock price and news, along with industry-best analysis. Cerevel Therapeutics Hldg Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. AbbVie/Cerevel made the merger announcement after market on Dec 6 Cerevel’s stock Get Cerevel Therapeutics Holdings Inc (CERE. 27. CERE has risen $1. President, Oncology at Pfizer Inc. 7 hours ago · The FTC is requesting more information on the merger between Cerevel Therapeutics and AbbVie. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of CAMBRIDGE, Mass. Oct 11, 2023. What is Cerevel Therapeutics Hldg's Beta? Apr 9, 2019 · In the news Cerevel Therapeutics Announces Publication of Phase 2a Study Results in Neurology on Its Most Advanced Investigational Epilepsy Treatment Findings Demonstrate Promising Anticonvulsant Activity with darigabat, a Novel Selective GABA Potentiator, in Patients with Photosensitive Epilepsy Company to Initiate Additional Phase 2 Study by Year-end to More Fully Characterize the Clinical The latest price target for . 4 million and $3. She has served as Cerevel’s Chief Financial Officer since May 2023. 27% gain for the Jul 2, 2021 · CAMBRIDGE, Mass. P) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Cerevel Therapeutics Holdings, Inc. 53. com. Unraveling the mysteries of the brain to treat neuroscience diseases Cerevel Therapeutics is working relentlessly to find paths through complexity in an effort to bring real progress and new treatment options to people living with some of the most devastating neuroscience diseases. stock information by Barron's. 4%. Aug 12, 2022 · Cerevel estimates that the net proceeds from the offering of common stock, after deducting underwriting discounts and commissions and estimated offering expenses payable by Cerevel, will be approximately $238. 2% above the current share price. Mar 1, 2022 · Stock. Kelly@pfizer. Cerevel Therapeutics Holdings, Inc. Pfizer Investors: Chuck Triano. S. E. Patricia. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. 50 per public warrant. historical stock charts and prices, analyst ratings, financials, and today’s real-time CERE stock price. Previously, he was a director at InVivo Therapeutics Holdings Corp. 00 and a low price target of $22. 00 per share, or approximately $253. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. BOSTON and TORONTO – July 27, 2020 – Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Cyclica, whose AI-augmented, integrated platform enables multi Nov 8, 2023 · CAMBRIDGE, Mass. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 19,728,189 shares of its common stock at a public offering Dec 7, 2023 · The purchase price of $45 represents a premium of almost 22% on Cerevel’s closing price of $36. DiPietro worked as the chief talent officer for Oak Hill Capital Partners and was a senior advisor to several Polaris Ventures portfolio companies. 64 in the next twelve months. stock was issued. Cerevel Therapeutics Holdings Insider Sold Shares Worth $331,608, According to a Recent SEC Filing. 5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The biotech company’s stock had climbed 42% since the end of last week Dec 6, 2023 · Cerevel Therapeutics experiences a 14% after-hours surge as Abbvie agreed to an $8. Cerevel Therapeutics prices $450M stock; What this means: Cerevel Therapeutics Holdings Inc. 72% while CERE is lower by -2. Common Stock (CERE) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. The shares were sold at an average price of $41. 651% from a day low at $43. Akamine joined Cerevel Therapeutics from AEON Biopharma, Inc. The price has been going up and down for this period, and there has been a 3. , and CAMBRIDGE, Mass. engages in the discovery and development of new therapies for neuroscience diseases. Oct 12, 2023 · Cerevel Therapeutics announces a $450M public offering, with underwriters having the option to purchase additional shares. Just prior, Mr. Dec. Charles. m. Feb 27, 2024 · Cerevel Therapeutics Holdings, Inc. 00. According to the issued ratings of 11 analysts in the last year, the consensus rating for Cerevel Therapeutics stock is Hold based on the current 9 hold ratings and 2 buy ratings for CERE. The analyst firm set a price target for 45. 38% while the S&P 500 is lower by -1. MT. after serving as executive vice president of human resources at Biogen Inc Jun 29, 2021 · Both doses of CVL-231 demonstrated a clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks and were overall well-tolerated compared with placebo 30 mg of CVL-231 once-daily improved PANSS total score at 6 weeks by 12. The analyst firm set a price target for $45. 5 days ago · A high-level overview of Cerevel Therapeutics Holdings, Inc. and other top-tier healthcare investors Upon A. stock news by MarketWatch. On average, Wall Street analysts predict. (CERE) gets an Overall Rank of 66, which is an above average rank under InvestorsObserver's stock ranking system. 00 expecting CERE to Jan 22, 2024 · Cerevel Therapeutics Holdings, Inc. ET. 00 About Cerevel Therapeutics of the proposed acquisition on the market price of AbbVie's common stock and/or operating Oct 11, 2023 · In addition, Cerevel granted the underwriters a 30-day option to purchase up to an additional 2,959,228 shares of its common stock at the public offering price, less underwriting discounts and 20 hours ago · In other Cerevel Therapeutics news, insider John Renger sold 2,161 shares of the business's stock in a transaction that occurred on Wednesday, February 7th. 27. 10% to the previous day’s close as strong demand from buyers drove the stock to $41. 3 million (or approximately $274. Price as of February 23, 2024, 4:00 p. stock price gained 0. Nov 13, 2022 · Cerevel Therapeutics Holdings, Inc. , July 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 14,000,000 shares of common stock at a public offering price of $25. 94. 00 and a low estimate of 25. Aug 12, 2022 · Cerevel also announced today the pricing of a public underwritten offering of 7,250,000 shares of its common stock at a public offering price of $35. Find out why we're neutral on CERE stock. Get the latest Cerevel Therapeutics Holdings Inc (CERE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and 4 days ago · Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock. , a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. , where he oversees Pfizer’s portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. 89% on the last trading day (Wednesday, 14th Feb 2024), rising from $42. 54, for a total transaction of $89,767. Dec 7, 2023 · Cerevel Therapeutics Holdings, Inc. 2 million 212-733-3810. 22. Akamine has served as our Chief Legal Officer and Corporate Secretary since May 2021. Cerevel Therapeutics Holdings Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, ann 5 months ago - GlobeNewsWire. ET on August 30, 2021 will be void and no longer exercisable, and the holders of those public warrants will Aug 10, 2022 · In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $37. 00, with a high estimate of 45. The company was founded in 2018 and is Feb 14, 2024 · The Cerevel Therapeutics Holdings, Inc. 30%. Oct 12, 2023 · In addition, Cerevel granted the underwriters a 30-day option to purchase up to an additional 2,959,228 shares of its common stock at the public offering price, less underwriting discounts and Dec 6, 2023 · AbbVie Inc. FRA): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Cerevel Therapeutics Holdings, Inc Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. , Dec. Jun 29, 2021 · June 29, 2021 at 4:24 PM EDT. What was the 52 6 days ago · View Cerevel Therapeutics Holdings, Inc CERE investment & stock information. that Cerevel Therapeutics Holdings's share price could reach $44. 00 per Aug 10, 2022 · The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Cerevel’s option at any time, and from time to time, on or after August 20, 2025 and on or before the 50th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Cerevel’s common stock Dec 6, 2023 · NORTH CHICAGO, Ill. 81. This suggests that the stock has a possible downside of 3. 13 by Feb 16, 2025. , Oct. Nov 1, 2023 · The Investor Relations website contains information about Cerevel Therapeutics's business for stockholders, potential investors, and financial analysts. , Nov. 023) Get the latest Cerevel Therapeutics Holdings, Inc. During the last trading day the stock fluctuated 0. View daily, weekly or monthly format back to when Cerevel Therapeutics Holdings, Inc. 62% from the current CERE share price of $41. CERE | Complete Cerevel Therapeutics Holdings Inc. Real time Cerevel Therapeutics (CERE) stock price quote, stock graph, news & analysis. 28. Varma was global president, rare diseases business unit, where he led one of Pfizer’s fastest-growing, high science units, which The latest closing stock price for Cerevel Therapeutics Holdings as of February 07, 2024 is 41. Chief Financial Officer. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Stock quote & chart; Analyst coverage; include $2. Feb 12, 2024 · NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. 64 on November 04, 2021. , June 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that is has commenced an underwritten public offering of 14,000,000 shares of its common stock. Over the past year the S&P 500 has gained 13. 85. Prior to joining us, Mr. 89 to $43. Cerevel Therapeutics Hldg (NASDAQ: CERE) was reported by JP Morgan on December 28, 2023. By Cory Renauer – Jun 29, 2021 at 12:35PM Current Price. Jul 27, 2020 · Cerevel will utilize Cyclica’s Ligand Express ® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines. The latest price target for Cerevel Therapeutics Hldg ( NASDAQ: CERE) was reported by JP Morgan on Thursday, December 28, 2023. Any such public warrants that remain unexercised following 5:00 p. 00 . 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that members of the management team will participate in two upcoming investor conferences during the Dec 6, 2023 · The North Chicago-based drugmaker is paying $45 a share in cash, a 22% premium to Cerevel’s closing price on Wednesday. zu sm qh aq oo en mi pj cc op